GlaxoSmithKline inks 5-year R&D pact with A*STAR

Pharma giant GlaxoSmithKline ($GSK) has inked a 5-year research pact with A*STAR's Institute of Chemical and Engineering Sciences (ICES) in Singapore, promising to collaborate on researching newly formulated drugs. The two groups have been working together for the past decade, helping build the city-state's reputation for R&D. "Collaborating with GSK, a global leader in pharmaceuticals and healthcare provides an opportunity for us to further our research and deepen our capabilities in formulation science with skilled scientists and technical expertise. This venture will enable us to develop future scientists and laboratory analysts with the right skills to grow this industry in Singapore," said Dr Keith Carpenter, the executive director of ICES. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.